Ascendiant Capital Markets Forecasts Strong Price Appreciation for Lucid Diagnostics (NASDAQ:LUCD) Stock

Lucid Diagnostics (NASDAQ:LUCD) had its price target upped by stock analysts at Ascendiant Capital Markets from $7.00 to $7.50 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other equities research analysts have also commented on LUCD. Needham & Company LLC restated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Friday, April 11th. BTIG Research set a $2.00 price target on Lucid Diagnostics in a report on Tuesday, March 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.00 price objective on shares of Lucid Diagnostics in a research note on Wednesday, March 26th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Lucid Diagnostics has an average rating of “Buy” and a consensus target price of $3.50.

Lucid Diagnostics Stock Up 11.0 %

LUCD stock opened at $1.21 on Monday. The firm has a market cap of $109.81 million, a price-to-earnings ratio of -1.06 and a beta of 1.26. The company’s fifty day simple moving average is $1.42 and its 200 day simple moving average is $1.08. Lucid Diagnostics has a 12-month low of $0.63 and a 12-month high of $1.80.

Institutional Trading of Lucid Diagnostics

Several hedge funds have recently bought and sold shares of LUCD. LPL Financial LLC raised its holdings in Lucid Diagnostics by 29.1% during the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after buying an additional 12,035 shares during the last quarter. Lido Advisors LLC raised its holdings in shares of Lucid Diagnostics by 40.0% in the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after acquiring an additional 40,000 shares during the last quarter. Geode Capital Management LLC lifted its position in Lucid Diagnostics by 30.9% in the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock valued at $229,000 after acquiring an additional 65,964 shares in the last quarter. Sunbelt Securities Inc. bought a new position in Lucid Diagnostics in the 4th quarter valued at about $67,000. Finally, Citadel Advisors LLC acquired a new position in Lucid Diagnostics during the 4th quarter valued at about $98,000. Institutional investors and hedge funds own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.